A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice

  1. Reem Abdel-Haq
  2. Johannes CM Schlachetzki
  3. Joseph C Boktor
  4. Thaisa M Cantu-Jungles
  5. Taren Thron
  6. Mengying Zhang
  7. John W Bostick
  8. Tahmineh Khazaei
  9. Sujatha Chilakala
  10. Livia H Morais
  11. Greg Humphrey
  12. Ali Keshavarzian
  13. Jonathan E Katz
  14. Matthew Thomson
  15. Rob Knight
  16. Viviana Gradinaru
  17. Bruce R Haymaker
  18. Christopher K Glass
  19. Sarkis K Mazmanian  Is a corresponding author
  1. California Institute of Technology, United States
  2. University of California, San Diego, United States
  3. Purdue University West Lafayette, United States
  4. University of Southern California, United States
  5. Rush University Medical Center, United States

Abstract

Parkinson's disease (PD) is a movement disorder characterized by neuroinflammation, α-synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in α-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces α-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for neuroinflammation and PD.

Data availability

All datasets generated or analyzed in this study can be found through the Zenodo depository: https://doi.org/10.5281/zenodo.6377704 All experimental protocols can be found on protocols.io.

The following data sets were generated

Article and author information

Author details

  1. Reem Abdel-Haq

    Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
  2. Johannes CM Schlachetzki

    Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
  3. Joseph C Boktor

    Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
  4. Thaisa M Cantu-Jungles

    Department of Food Science, Purdue University West Lafayette, West Lafayette, United States
    Competing interests
    Thaisa M Cantu-Jungles, has equity in RiteCarbs, a company developing prebiotic diets for Parkinson's disease..
  5. Taren Thron

    Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
  6. Mengying Zhang

    Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
  7. John W Bostick

    Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
  8. Tahmineh Khazaei

    Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
  9. Sujatha Chilakala

    Lawrence J Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, United States
    Competing interests
    No competing interests declared.
  10. Livia H Morais

    Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5738-2658
  11. Greg Humphrey

    Department of Pediatrics, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
  12. Ali Keshavarzian

    Department of Internal Medicine, Rush University Medical Center, Chicago, United States
    Competing interests
    Ali Keshavarzian, has equity in RiteCarbs, a company developing prebiotic diets for Parkinson's disease.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7969-3369
  13. Jonathan E Katz

    Lawrence J Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, United States
    Competing interests
    No competing interests declared.
  14. Matthew Thomson

    Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
  15. Rob Knight

    Department of Pediatrics, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
  16. Viviana Gradinaru

    Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5868-348X
  17. Bruce R Haymaker

    Department of Food Science, Purdue University West Lafayette, West Lafayette, United States
    Competing interests
    Bruce R Haymaker, has equity in RiteCarbs, a company developing prebiotic diets for Parkinson's disease.
  18. Christopher K Glass

    Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4344-3592
  19. Sarkis K Mazmanian

    Biology and Biological Engineering Department, California Institute of Technology, Pasadena, United States
    For correspondence
    sarkis@caltech.edu
    Competing interests
    Sarkis K Mazmanian, has equity in Axial Therapeutics, a company developing gut-restricted drugs for Parkinson's disease..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2713-1513

Funding

U.S. Department of Defense (PD160030)

  • Sarkis K Mazmanian

Heritage Medical Research Institute (HMRI-15-09-01)

  • Sarkis K Mazmanian

Aligning Science Across Parkinson's (ASAP-000375)

  • Sarkis K Mazmanian

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were done under the guidance and approval of Caltech's Institutional Animal Care and Use Committee (IACUC).

Copyright

© 2022, Abdel-Haq et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,525
    views
  • 419
    downloads
  • 30
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Reem Abdel-Haq
  2. Johannes CM Schlachetzki
  3. Joseph C Boktor
  4. Thaisa M Cantu-Jungles
  5. Taren Thron
  6. Mengying Zhang
  7. John W Bostick
  8. Tahmineh Khazaei
  9. Sujatha Chilakala
  10. Livia H Morais
  11. Greg Humphrey
  12. Ali Keshavarzian
  13. Jonathan E Katz
  14. Matthew Thomson
  15. Rob Knight
  16. Viviana Gradinaru
  17. Bruce R Haymaker
  18. Christopher K Glass
  19. Sarkis K Mazmanian
(2022)
A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice
eLife 11:e81453.
https://doi.org/10.7554/eLife.81453

Share this article

https://doi.org/10.7554/eLife.81453

Further reading

    1. Microbiology and Infectious Disease
    Srinivasan Vijay, Nguyen Le Hoai Bao ... Nguyen Thuy Thuong
    Research Article

    Antibiotic tolerance in Mycobacterium tuberculosis reduces bacterial killing, worsens treatment outcomes, and contributes to resistance. We studied rifampicin tolerance in isolates with or without isoniazid resistance (IR). Using a minimum duration of killing assay, we measured rifampicin survival in isoniazid-susceptible (IS, n=119) and resistant (IR, n=84) isolates, correlating tolerance with bacterial growth, rifampicin minimum inhibitory concentrations (MICs), and isoniazid-resistant mutations. Longitudinal IR isolates were analyzed for changes in rifampicin tolerance and genetic variant emergence. The median time for rifampicin to reduce the bacterial population by 90% (MDK90) increased from 1.23 days (IS) and 1.31 days (IR) to 2.55 days (IS) and 1.98 days (IR) over 15–60 days of incubation, indicating fast and slow-growing tolerant sub-populations. A 6 log10-fold survival fraction classified tolerance as low, medium, or high, showing that IR is linked to increased tolerance and faster growth (OR = 2.68 for low vs. medium, OR = 4.42 for low vs. high, p-trend = 0.0003). High tolerance in IR isolates was associated with rifampicin treatment in patients and genetic microvariants. These findings suggest that IR tuberculosis should be assessed for high rifampicin tolerance to optimize treatment and prevent the development of multi-drug-resistant tuberculosis.